The "Device" is increasingly being engineered at the molecular level. In 2025, the use of nanocomposites and specialized polymers is allowing for the delivery of "unstable" drugs that would otherwise degrade before reaching their destination. This includes the use of lipid nanoparticles (LNPs), which were made famous by mRNA vaccines but are now being used in various delivery devices to protect genetic therapies.

Research from the Drug Delivery Devices Market suggests that material biocompatibility is the #1 R&D priority. As devices stay in contact with the body for longer (in the case of wearables and implants), the risk of "foreign body response" increases. Manufacturers are developing "Bio-Inert" coatings that prevent the body's immune system from attacking the device, ensuring consistent drug release rates over long periods.

Glass remains the standard for primary packaging (vials and syringes), but "Advanced Polymers" like Cyclo-Olefin Polymer (COP) are gaining share. COP is shatter-resistant and has lower "leachable and extractable" profiles than glass, which is vital for the stability of modern biologics. In 2025, the move toward "Silicon-Free" delivery systems is also a key trend, as silicone oil (used to lubricate syringes) can sometimes cause proteins in the drug to "clump," rendering the therapy ineffective.